CRBU vs. GLUE, MGX, AURA, ADPT, ALVO, SLDB, MGTX, OCGN, HUMA, and AVXL
Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Monte Rosa Therapeutics (GLUE), Metagenomi (MGX), Aura Biosciences (AURA), Adaptive Biotechnologies (ADPT), Alvotech (ALVO), Solid Biosciences (SLDB), MeiraGTx (MGTX), Ocugen (OCGN), Humacyte (HUMA), and Anavex Life Sciences (AVXL). These companies are all part of the "biological products, except diagnostic" industry.
Monte Rosa Therapeutics (NASDAQ:GLUE) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
In the previous week, Caribou Biosciences had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 3 mentions for Caribou Biosciences and 2 mentions for Monte Rosa Therapeutics. Caribou Biosciences' average media sentiment score of 1.24 beat Monte Rosa Therapeutics' score of 0.56 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.
Monte Rosa Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500.
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 5.3% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Caribou Biosciences received 6 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 50.00% of users gave Caribou Biosciences an outperform vote while only 37.50% of users gave Monte Rosa Therapeutics an outperform vote.
Caribou Biosciences has higher revenue and earnings than Monte Rosa Therapeutics. Caribou Biosciences is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Monte Rosa Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -296.05%. Monte Rosa Therapeutics' return on equity of -31.06% beat Caribou Biosciences' return on equity.
Monte Rosa Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 88.03%. Caribou Biosciences has a consensus price target of $22.50, suggesting a potential upside of 484.42%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Monte Rosa Therapeutics.
Summary
Caribou Biosciences beats Monte Rosa Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Caribou Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Caribou Biosciences Competitors List
Related Companies and Tools
